Cell line · CVCL_0454
Papers52
1 to 20 of 52
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Enabling subcellular DESI-MSI for broad adoption: Acquisition, analysis, and application. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBM25 Drives Hepatocellular Carcinoma Progression by Stabilizing YAP Through Regulating Oncogenic Splicing-switch of MYPT1. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An SLCO2B1 mRNA Isoform Acts as a Noncoding RNA to Drive Cancer Progression by Triggering Protein Biosynthesis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TGFβ1 Activates Lnc-APUE to Promote Tumor Metastasis via the Alu Element-Driven STAU1-Mediated Decay of CDH1 mRNA. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mechanical Stimuli-Induced Manipulation of Malignant Behavior in Bioprinted Cancer Microtissues via PI3K/NF-κB Activation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel candidate tumor biomarker progestin and adipoQ receptor 3 regulates cell metastasis through transforming growth factor-β pathway in hepatocellular carcinoma. | Cytojournal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Peptide‑based therapeutics targeting the SLC39A14‑PIWIL2 fusion in hepatocellular carcinoma. | Genomics Inform | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Magnetic Resonance Imaging Using a Chimeric Anti-Glypican-3 Antibody Conjugated with Gadolinium Selectively Detects Glypican-3-Positive Hepatocellular Carcinoma In Vitro and In Vivo. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell transcriptomics identifies an H2AFZ-driven proliferative tumor subpopulation associated with poor prognosis in hepatocellular carcinoma. | Front Mol Biosci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment. | J Immunother Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0454/papers